Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance (2020)
Source: Pharmacological Research. Unidades: FCF, FM
ABNT
SANDRIA, Silvana et al. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. Pharmacological Research, v. 159, p. 1-19 art. 104998, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.phrs.2020.104998. Acesso em: 02 set. 2024.APA
Sandria, S., Watanabe, L. R. M., Oliveira, E. A. de, Flores, F. F., Migliorini, S., Tiago, M., et al. (2020). Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. Pharmacological Research, 159, 1-19 art. 104998. doi:10.1016/j.phrs.2020.104998NLM
Sandria S, Watanabe LRM, Oliveira EA de, Flores FF, Migliorini S, Tiago M, Silva ASF da, Vazquez V de L, Souza P da C, Consolaro MEL, Campa A, Maria-Engler SS. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance [Internet]. Pharmacological Research. 2020 ; 159 1-19 art. 104998.[citado 2024 set. 02 ] Available from: https://doi.org/10.1016/j.phrs.2020.104998Vancouver
Sandria S, Watanabe LRM, Oliveira EA de, Flores FF, Migliorini S, Tiago M, Silva ASF da, Vazquez V de L, Souza P da C, Consolaro MEL, Campa A, Maria-Engler SS. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance [Internet]. Pharmacological Research. 2020 ; 159 1-19 art. 104998.[citado 2024 set. 02 ] Available from: https://doi.org/10.1016/j.phrs.2020.104998